Scholar Rock (SRRK) Competitors $44.34 -0.44 (-0.98%) (As of 03:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SRRK vs. MRNA, VTRS, SMMT, GMAB, RDY, SRPT, CTLT, PCVX, QGEN, and ITCIShould you be buying Scholar Rock stock or one of its competitors? The main competitors of Scholar Rock include Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), Vaxcyte (PCVX), Qiagen (QGEN), and Intra-Cellular Therapies (ITCI). These companies are all part of the "pharmaceutical products" industry. Scholar Rock vs. Moderna Viatris Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Sarepta Therapeutics Catalent Vaxcyte Qiagen Intra-Cellular Therapies Moderna (NASDAQ:MRNA) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability, community ranking and analyst recommendations. Is MRNA or SRRK more profitable? Scholar Rock has a net margin of 0.00% compared to Moderna's net margin of -43.77%. Moderna's return on equity of -17.68% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-43.77% -17.68% -13.35% Scholar Rock N/A -145.60%-91.83% Does the media refer more to MRNA or SRRK? In the previous week, Moderna had 16 more articles in the media than Scholar Rock. MarketBeat recorded 18 mentions for Moderna and 2 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.73 beat Moderna's score of 0.16 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 3 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Scholar Rock 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Does the MarketBeat Community favor MRNA or SRRK? Moderna received 47 more outperform votes than Scholar Rock when rated by MarketBeat users. However, 65.74% of users gave Scholar Rock an outperform vote while only 55.21% of users gave Moderna an outperform vote. CompanyUnderperformOutperformModernaOutperform Votes21255.21% Underperform Votes17244.79% Scholar RockOutperform Votes16565.74% Underperform Votes8634.26% Which has higher earnings and valuation, MRNA or SRRK? Scholar Rock has lower revenue, but higher earnings than Moderna. Scholar Rock is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$5.06B3.00-$4.71B-$5.82-6.77Scholar Rock$33.19M126.31-$165.79M-$2.35-19.06 Do analysts recommend MRNA or SRRK? Moderna currently has a consensus price target of $79.50, indicating a potential upside of 101.83%. Scholar Rock has a consensus price target of $40.43, indicating a potential downside of 9.72%. Given Moderna's higher possible upside, equities analysts clearly believe Moderna is more favorable than Scholar Rock.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 12 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.14Scholar Rock 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Which has more risk & volatility, MRNA or SRRK? Moderna has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Do institutionals and insiders believe in MRNA or SRRK? 75.3% of Moderna shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 15.7% of Moderna shares are owned by insiders. Comparatively, 19.2% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryScholar Rock beats Moderna on 10 of the 18 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Scholar Rock News Delivered to You Automatically Sign up to receive the latest news and ratings for SRRK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRRK vs. The Competition Export to ExcelMetricScholar RockBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.19B$2.94B$5.15B$9.08BDividend YieldN/A1.90%5.12%4.25%P/E Ratio-19.0646.7387.1117.18Price / Sales126.31415.061,116.56117.12Price / CashN/A182.1043.2337.85Price / Book14.353.894.794.78Net Income-$165.79M-$42.21M$120.55M$225.60M7 Day Performance4.46%-2.36%-1.49%-1.36%1 Month Performance49.67%1.83%13.65%0.20%1 Year Performance138.83%16.78%28.61%15.30% Scholar Rock Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRRKScholar Rock3.9955 of 5 stars$44.34-1.0%$40.43-8.8%+138.8%$4.15B$33.19M-18.87140Positive NewsMRNAModerna4.261 of 5 stars$41.59-0.6%$79.50+91.2%-58.5%$16.00B$5.06B-7.195,600VTRSViatris2.8187 of 5 stars$12.71+0.6%$13.67+7.5%+17.6%$15.17B$15.05B-17.0738,000SMMTSummit Therapeutics3.1244 of 5 stars$18.71+4.9%$33.33+78.2%+654.0%$13.80B$700,000.00-63.68105GMABGenmab A/S4.233 of 5 stars$20.14-0.1%$45.20+124.4%-35.4%$13.33B$19.84B19.582,204Positive NewsHigh Trading VolumeRDYDr. Reddy's Laboratories1.9394 of 5 stars$14.75+2.0%$17.00+15.3%+14.1%$12.31B$299.87B22.9527,048SRPTSarepta Therapeutics4.7725 of 5 stars$126.12+1.9%$178.71+41.7%+25.8%$12.05B$1.64B98.971,314CTLTCatalent2.5872 of 5 stars$63.48+0.7%$63.40-0.1%N/A$11.52B$4.38B-27.9116,900High Trading VolumePCVXVaxcyte1.5581 of 5 stars$90.59+3.3%$147.50+62.8%+41.7%$11.29BN/A-19.07160Analyst ForecastQGENQiagen3.6176 of 5 stars$45.41+0.0%$51.15+12.6%+0.3%$10.36B$1.97B117.035,967ITCIIntra-Cellular Therapies4.0655 of 5 stars$84.54+1.8%$97.23+15.0%+18.6%$8.96B$612.78M-95.91560Positive News Related Companies and Tools Related Companies MRNA Competitors VTRS Competitors SMMT Competitors GMAB Competitors RDY Competitors SRPT Competitors CTLT Competitors PCVX Competitors QGEN Competitors ITCI Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SRRK) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scholar Rock Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scholar Rock With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SRRK Stock Alerts